War against respiratory syncytial virus

References

1. ↵
   1. Nair H,
   2. Nokes DJ,
   3. Gessner BD,
   4. Dherani M,
   5. Madhi SA,
   6. Singleton RJ,
   7. et al.

   (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children:a systematic review and meta-analysis. Lancet 375:1545–1555.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Lozano R,
   2. Naghavi M,
   3. Foreman K,
   4. Lim S,
   5. Shibuya K,
   6. Aboyans V,
   7. et al.

   (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Turner TL,
   2. Kopp BT,
   3. Paul G,
   4. Landgrave LC,
   5. Hayes D Jr.,
   6. Thompson R

   (2014) Respiratory syncytial virus:current and emerging treatment options. Clinicoecon Outcomes Res 6:217–225.

   OpenUrl
4. ↵
   1. Langley GF,
   2. Anderson LJ

   (2011) Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J 30:510–517.

   OpenUrlCrossRefPubMed
5. ↵
   1. Glezen WP,
   2. Taber LH,
   3. Frank AL,
   4. Kasel JA

   (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140:543–546.

   OpenUrlCrossRefPubMed
6. ↵
   1. Kudhari P,
   2. Brosio F,
   3. Malaventura C,
   4. Stefanati A,
   5. Orsi A,
   6. Icardi G,
   7. et al.

   (2018) Human respiratory syncytial virus and hospitalization in young children in Italy. Italian J Pediatrics 44:50.

   OpenUrl
7. ↵
   1. Régnier SA,
   2. Huels J

   (2013) Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae:systematic review and meta-analysis. J. Pediatr Infect Dis J. 32:820–826.

   OpenUrl
8. ↵
   1. Bakir TM,
   2. Halwani M,
   3. Ramia S

   (1998) Viral aetiology and epidemiology of acute respiratory infections in hospitalized Saudi children. J Trop Pediatr 44:100–103.

   OpenUrlCrossRefPubMed
9. ↵
   1. Shay DK,
   2. Holman RC,
   3. Newman RD,
   4. Lui LL,
   5. Stout JW,
   6. Anderson LJ

   (1999) Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440–1446.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Ralston SL,
    2. Lieberthal AS,
    3. Meissner HC,
    4. Baley JE,
    5. Gadomski AM,
    6. Johnson DW,
    7. et al.

    (2014) Clinical practice guideline:the diagnosis, management, and prevention of bronchiolitis. Pediatrics 134:e1474–e1502.

    OpenUrlAbstract/FREE Full Text
11. ↵
    1. Resch B

    1. Akhter J,
    2. Al Johani S

    (2011) in Human Respiratory Syncytial Virus Infection, Epidemiology and Diagnosis of Human Respiratory Syncytial Virus Infections, ed Resch B (InTech Europe, Rijeka (HR)), pp 161–176.
12. ↵
    1. Huang K,
    2. Incognito L,
    3. Cheng X,
    4. Nancy D,
    5. Wu U,
    6. Wu H

    (2010) Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol 84:8132–8140.

    OpenUrlAbstract/FREE Full Text
13. ↵
    (1998) Prevention of respiratory syncytial virus infections:indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 102:1211–1216.

    OpenUrlAbstract/FREE Full Text
14. 1. Pickering LK,
    2. Baker CJ,
    3. Kimberlin DW,
    4. Long SS

    1. American Academy of Pediatrics

    (2001) Red Book:2012 Report of the Committee on Infectious Diseases, eds Pickering LK, Baker CJ, Kimberlin DW, Long SS (American Academy of Pediatrics, Elk Grove Village, IL), 29th ed, 2, p 609.

    OpenUrl
15. ↵
    1. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee

    (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134:415–420.

    OpenUrlAbstract/FREE Full Text
16. ↵
    (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk infants. The IMpact-RSV Study Group. Pediatrics 102:531–537.

    OpenUrlAbstract/FREE Full Text
17. ↵
    1. Hall CB,
    2. Weinberg GA,
    3. Blumkin AK,
    4. Edwards KM,
    5. Staat MA,
    6. Schultz AF,
    7. et al.

    (2013) Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 132:e341–e348.

    OpenUrlAbstract/FREE Full Text
18. 1. Stevens TP,
    2. Sinkin RA,
    3. Hall CB,
    4. Maniscalco WM,
    5. McConnochie KM

    (2000) Respiratory syncytial virus and premature infants born at 32 weeks'gestation or earlier:hospitalization and economic implications of prophylaxis. Arch PediatrAdolesc Med 154:55–61.

    OpenUrl
19. ↵
    1. Boyce TG,
    2. Mellen BG,
    3. Mitchel EF Jr.,
    4. Wright PF,
    5. Griffin MR

    (2000) Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 137:865–870.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Winterstein AG,
    2. Knox CA,
    3. Kubilis P,
    4. Hampp C

    (2013) Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants:a cohort study. JAMA Pediatr 167:1118–1124.

    OpenUrl
21. ↵
    1. Feltes TF,
    2. Cabalka AK,
    3. Meissner HC,
    4. Piazza FM,
    5. Carlin DA,
    6. Top FH Jr.,
    7. et al.

    (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143:532–540.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    1. Chang RK,
    2. Chen AY

    (2010) Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease. PediatrCardiol 31:90–95.

    OpenUrlCrossRefPubMed
23. ↵
    1. Bodenhetmer T

    (1999) Disease management - promises and pitfalls. N Engl J Med 340:1202–1205.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    1. Bont L,
    2. Checchia PA,
    3. Fauroux B,
    4. Figueras-Aloy J,
    5. Manzoni P,
    6. Paes B,
    7. et al.

    (2016) Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther 5:271–298.

    OpenUrl